Clinical Research Directory
Browse clinical research sites, groups, and studies.
First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy
Sponsor: Nerissa T. Viola
Summary
The goal of this clinical trial is to investigate the use of \[89Zr\]Zr-DFO-emapalumab as an IFN-γ PET imaging agent to detect lesions and response to therapy among treatment-naïve non-small cell lung cancer (NSCLC) patients. PET scans following the imaging agent will be completed prior to and about 30 days after starting immunotherapy.
Official title: IFN-y PET Imaging: Bench to Bedside
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
6
Start Date
2026-03-09
Completion Date
2029-06
Last Updated
2026-03-11
Healthy Volunteers
No
Conditions
Interventions
[89Zr]Zr-DFO-emapalumab
Radiotracer \[89Zr\]Zr-DFO-emapalumab administration followed by 3 PET Scans (day 0, day 1 and day 3-5) within 14 days of starting immunotherapy and repeated once 25-45 days after immunotherapy started
Locations (1)
Karmanos Cancer Institute
Detroit, Michigan, United States